


## Synthesis of a Miniature Lipoarabinomannan

Jian Gao,<sup>†,§</sup> Guochao Liao,<sup>†,§</sup> Lizhen Wang,<sup>‡</sup> and Zhongwu Guo<sup>\*,†,‡</sup><sup>†</sup>Department of Chemistry, Wayne State University, Detroit, Michigan 48202, United States<sup>‡</sup>National Glycoengineering Research Center, Shandong University, Jinan 250100, China

## S Supporting Information

**ABSTRACT:** An analog of *Mycobacterium tuberculosis* lipoarabinomannan (LAM) has been synthesized containing the characteristic structures of all of its three major components; that is, a mannosylated phosphatidylinositol moiety, an oligomannan, and an oligoarabinan. A highly convergent strategy was developed that is applicable to the synthesis of other LAM analogs. The synthetic miniature LAM should be useful for various biological studies.



Tuberculosis (TB) claims more than two million lives each year. Despite the enormous endeavor to combat this epidemic, there is still a trend of TB resurgence recently.<sup>1</sup> Consequently, developing new TB therapies, in particular effective TB vaccines, has become an urgent topic.<sup>2,3</sup> For this purpose, lipoarabinomannan (LAM), one of the major lipopolysaccharides in the cell envelope of *Mycobacterium tuberculosis* (*Mtb*), the causative pathogen of TB, and other mycobacteria as well, has attracted significant attention, as LAM is not only essential for mycobacterial growth and cell viability but also a major virulence factor that plays a critical role in bacterium interactions with the host immune system.<sup>4–8</sup> Furthermore, LAMs have been revealed to be exposed on the bacterial cell surfaces,<sup>9</sup> rendering them an ideal target for TB vaccine development.<sup>10</sup>

Although structurally diverse, LAMs share a conserved construct having a phospholipid, a lipidated mannose, and a complex arabinomannan polysaccharide attached to the *myo*-inositol 1-*O*-, 2-*O*-, and 6-*O*-positions, respectively, as shown in Figure 1.<sup>4,11</sup> In turn, arabinomannan consists of an inositol-attached mannan with an  $\alpha$ -1,6-linked backbone and an

arabinan with an  $\alpha$ -1,5-linked backbone having 3-*O*-branches. There are additional mannose units randomly attached to the mannan 2-*O*-positions. Moreover, in some mycobacterial strains, there are short oligomannose caps at the arabinan nonreducing end to form mannosylated LAMs.<sup>12,13</sup> It is interesting to observe that arabinomannans derived from some fast-growing *Mycobacterium* species were devoid of the mannose cap.<sup>12</sup>

Owing to its intriguing structure and bioactivity, LAM has become a popular subject for synthetic studies. As a result, a variety of LAM fragments or partial structures, such as arabinomannans, phosphatidylinositol mannosides (PIMs), and lipomannans (LMs), have been prepared and studied.<sup>14–37</sup> However, to the best of our knowledge, there has been no reported synthesis of LAM analogs containing all its three major components, namely, mannan, arabinan, and phosphatidylinositol. In view of the great potential of this type of LAM analog for studying the biological and immunological functions of LAMs, for developing LAM-based vaccines, and so on,<sup>5,8,10</sup> we designed and prepared a miniature LAM **1** (Figure 1), which had a phospholipid, a lipidated mannose, and a short arabinomannan attached to the inositol 1-*O*-, 2-*O*-, and 6-*O*-positions, respectively. In LAMs, the linkage of arabinan to mannan has not been unequivocally proven, but it is most likely at the mannose 2-*O*-position.<sup>4</sup> In our synthetic target, arabinan is attached to the alternative 6-*O*-position. Nevertheless, as discussed below, the two types of LAM analogs can be prepared by the same generally applicable synthetic strategy.

Our synthetic plan for the target molecule **1** is depicted in Scheme 1. Since **1** contained acyl lipids in its structure, benzyl (Bn) ethers would be utilized as global protecting groups for





Figure 1. Structures of LAM and a LAM analog **1**.

Received: December 22, 2013


## Scheme 1. Retrosynthesis of the Target Molecule 1



the hydroxyls (2), which could potentially be readily deprotected without affecting the lipids. The lipids would be installed in the final stages, just before global deprotection, leading to a key intermediate 3 that had the 1-O-position of inositol and the 6-O-position of inositol 2-O-position-linked mannose orthogonally protected with the *p*-methoxybenzyl (PMB) and *tert*-butyldimethylsilyl (TBS) groups, respectively. For 3, all of the 2-O-positions in the oligoarabinomannan moiety would be protected as acetates to ensure  $\alpha$ -specific glycosylation reactions during the oligosaccharide assembly, owing to neighboring group participation. Disconnecting the glycosidic bond between the first and second mannose residues in 3 generated the heptasaccharide 5 and the pseudotrisaccharide 6. Notably, this synthetic design would entail attachment of an oligomannosyl donor to a relatively reactive primary alcohol by an  $\alpha$ -linkage that could be relatively easily and effectively realized. Orthogonally protected 6 was a rather versatile intermediate useful for the synthesis of various PIM, LM, and LAM analogs and related structures, as demonstrated in our previous synthesis of an LM derivative.<sup>38</sup> On the other hand, 5 could be assembled from 8–11, all of which were thioglycosides that would enable preactivation-based glycosylation reactions and one-pot synthesis. Moreover, it was anticipated that this synthetic strategy would be also applicable to LAM analogs having arabinans linked to the mannose 2-O-position, starting from a mannose derivative with an uniquely protected 2-O-position, instead of 10.

Monosaccharide building blocks 8 and 9 were prepared from peracetylated D-arabinofuranose 12 (Scheme 2).<sup>39</sup> Bromination of 12, followed by intramolecular cyclization in the presence of 2,6-lutidine and deacetylation, afforded orthoester 13. Perbenzylation of 13 and SnCl<sub>4</sub>-promoted glycosylation with *p*-thiocresol (TolSH), via ring opening of the orthoester, produced 8, which was obtained from 12 in five steps in a


## Scheme 2. Synthesis of 6 and 7



38% overall yield. En route to 9, the two free hydroxyl groups in 13 were differentiated after regioselective silylation of the 5-OH group using TBSCl and benzoylation of the 3-OH group to give 14. Finally, 14 was transformed into 9 after glycosylation with TolSH and SnCl<sub>4</sub>, as described above, and desilylation mediated by tetra-*n*-butylammonium fluoride (TBAF).

Tetramannose 7 was convergently assembled by means of the preactivation-based glycosylation protocol (Scheme 3).<sup>40</sup>


## Scheme 3. Synthesis of Tetrasaccharide 7



After 10<sup>38</sup> was activated at low temperature (−78 °C) with *p*-toluenesulfonyl triflate (TolSOTf) produced *in situ* from the reaction of *p*-toluenesulfonyl chloride (TolSOCl) and silver triflate (AgOTf), 11 was added to achieve the glycosylation. This reaction was  $\alpha$ -stereoselective, giving the disaccharide 15 in excellent yield (85%). Treatment of 15 with Et<sub>3</sub>N·3HF to remove the TBS group gave alcohol 16. Its glycosylation with 15 was achieved by the same preactivation protocol to give tetrasaccharide 17, of which all of the glycosidic linkages had an  $\alpha$ -configuration, proved by the observed anomeric C–H coupling constants, which ranged from 169 to 175 Hz.<sup>41</sup> Consecutively, the TBS protection was removed with Et<sub>3</sub>N·3HF to produce 7 as a glycosyl acceptor for further sugar chain elongation.

Heptasaccharide 5 was constructed from monosaccharides 8 and 9 and tetrasaccharide 7 (Scheme 4) according to the preactivation-based iterative one-pot glycosylation protocol.<sup>40</sup> Although this protocol has been quite broadly utilized in the synthesis of pyranosidic oligosaccharides, there are relatively few reports related to its application to furanosyl oligosaccharides.<sup>26,28</sup> For each glycosylation, the thioglycosyl donor was first preactivated at −78 °C for 10 min with *in situ* generated TolSOTf as the promoter, and the coupling reaction was carried out at room temperature for *ca.* 20 min after the addition of a glycosyl acceptor in conjunction with 2,4,6-*tert*-butylpyrimidine (TTBP), a sterically hindered base that was employed as a scavenger for trifluoromethanesulfonic acid formed from the reaction. A stoichiometric amount (1.0 equiv) of TolSOTf and 0.9 equiv of an acceptor (relative to the donor)

## Scheme 4. Synthesis of Glycosylated Inositol 3




were applied to each glycosylation to guarantee complete consumption of the acceptor, so as to minimize potential interference with the following reactions. Eventually, **5** was isolated in a 41% overall yield, suggesting an average of a 75% yield for each glycosylation reaction. As a result of neighboring group participation, the glycosylation reactions were  $\alpha$ -selective, since the anomeric carbon signals of all three newly formed arabinosyl linkages appeared at over 106.0 ppm, proving the  $\alpha$ -configuration.<sup>42,43</sup> Compared to traditional methods utilized to prepare oligosaccharides, the use of preactivation glycosylation saved several steps in the glycosyl donor manipulation, e.g., anomeric deprotection and activation, and enabled the one-pot synthesis to decrease the number of laborious column purification operations. Both helped to improve the overall synthetic efficiency. Our previous experience suggested that when complex oligosaccharides were used as glycosyl donors Schmidt glycosylation gave better results than thioglycosides.<sup>38</sup> We therefore converted **5** into the trichloroacetimidate **18** following *N*-iodosuccinimide (NIS)-promoted hydrolysis of the thioglycoside and reaction of the resulting hemiacetal with trichloroacetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Finally, **6**<sup>38</sup> was glycosylated with **18** and trimethylsilyl triflate (TMSOTf), affording glycosylated inositol **3** stereoselectively in very good yield (79%). This result was especially impressive, considering the complex glycosyl donor and acceptor involved in the reaction. As planned, participation of the neighboring acetyl group in **18** assisted the glycosylation reaction with the relatively reactive primary alcohol of glycosyl acceptor **6**. The structure of **3** was confirmed by MS and NMR spectra. For example, the <sup>13</sup>C NMR (150 MHz, in CDCl<sub>3</sub>) spectrum of **3** displayed eight distinctive anomeric carbon signals at  $\delta$  106.2 ( $\alpha$ -Ara), 106.0 ( $\alpha$ -Ara), 106.0 ( $\alpha$ -Ara), 98.6 ( $\alpha$ -Man), 98.3 ( $\alpha$ -Man), 98.26 ( $\alpha$ -Man), 98.21 ( $\alpha$ -Man), 98.1 ( $\alpha$ -Man), and 97.9 ( $\alpha$ -Man), with anomeric <sup>1</sup>J<sub>C,H</sub> values for the mannosyl units ranging from 172 to 176 Hz.

The endgame of this synthesis involved swapping the acetyl groups in **3** for benzyl protecting groups to allow regioselective

installation of the lipids and complete global deprotection to give the target molecule (Scheme 5). First, **3** was deacetylated

## Scheme 5. Final Assembly of the LAM Analog 1



with sodium methoxide (NaOMe) in methanol (MeOH). This was followed by *O*-benzylation with BnBr and tetrabutylammonium iodide (TBAI). Next, the TBS group in the resultant **19** was selectively removed with Et<sub>3</sub>N·3HF, which paved the way for acylation of the 6-*O*-position with stearic acid using *N,N'*-dicyclohexylcarbodiimide (DCC) as the condensation reagent to afford **21**. Then, the inositol 1-*O*-position was phosphoglycerolipidated after selective removal of the PMB group in **21**. In view of the fact that the furanosyl arabinosides are rather acid labile,<sup>18</sup> we treated **21** with a very diluted (2%) trifluoroacetic acid (TFA) solution in dichloromethane (DCM) for a short period (6 h) for PMB group removal, which gave a 54% yield of **22** together with recovery of a significant amount of the starting material **21** (ca. 29%). Phosphoglycerolipidation of **22** by the two-step one-pot phosphoramidite method was smooth, upon reaction with freshly prepared **4** in the presence of 1*H*-tetrazole and *in situ* oxidation using *meta*-chloroperoxybenzoic acid (*m*-CPBA), generating **2** (70%) as a diastereomeric mixture (1:1) due to the stereogenic phosphorus atom. Finally, global debenzoylation of **2** was achieved under a hydrogen atmosphere using 10% Pd/

C as the catalyst in a mixture of chloroform, methanol, and water (3:3:1) to obtain the synthetic target **1**, which was confirmed by  $^1\text{H}$  and  $^{31}\text{P}$  NMR spectrometry and MALDI-TOF MS.

In summary, we have achieved the first LAM mimic **1** that contained all of the three main components of LAMs by a highly convergent synthetic strategy. As a miniature LAM having homogeneous and defined structure, **1** should be useful for various biological and immunological studies of LAMs and for the development of LAM-based TB vaccines. We are currently working on the synthesis of a series of LAM analogs by the strategy described here and are using them to probe the structure–immunological activity relationships of LAMs.

## ■ ASSOCIATED CONTENT

### ● Supporting Information

Experimental procedures,  $^1\text{H}$ ,  $^{13}\text{C}$ , and  $^{31}\text{P}$  NMR spectra of the synthetic intermediates and the final products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [zwguo@chem.wayne.edu](mailto:zwguo@chem.wayne.edu); [zwguo@sdu.edu.cn](mailto:zwguo@sdu.edu.cn).

### Author Contributions

§These authors contributed equally.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This work was supported in part by the National Major Scientific and Technological Special Project for New Drugs Development (2012ZX09502001), National High Technology Research and Development (863) Program of China (2012AA021504), and the National Institutes of Health (R01 GM090270).

## ■ REFERENCES

- (1) Raviglione, M. C.; Smith, I. M. *N. Engl. J. Med.* **2007**, 356, 656.
- (2) Russell, D. G. *Nat. Rev. Mol. Cell Biol.* **2001**, 2, 569.
- (3) Sacchettini, J. C.; Rubin, E. J.; Freundlich, J. S. *Nat. Rev. Microbiol.* **2008**, 6, 41.
- (4) Brennan, P. J.; Nikaido, H. *Annu. Rev. Biochem.* **1995**, 64, 29.
- (5) Vercellone, A.; Nigou, J.; Puzo, G. *Front. Biosci.* **1998**, 3, E149.
- (6) Koul, A.; Herget, T.; Klebl, B.; Ullrich, A. *Nat. Rev. Microbiol.* **2004**, 2, 189.
- (7) Russell, D. G. *Nat. Rev. Microbiol.* **2007**, 5, 39.
- (8) Briken, V.; Porcelli, S. A.; Besra, G. S.; Kremer, L. *Mol. Microbiol.* **2004**, 53, 391.
- (9) Pitarque, S.; Larrouy-Maumus, G.; Payre, B.; Jackson, M.; Puzo, G.; Nigou, J. *Tuberculosis* **2008**, 88, 560.
- (10) Flynn, J. L. *Tuberculosis* **2004**, 84, 93.
- (11) Nigou, J.; Gilleron, M.; Puzo, G. *Biochimie* **2003**, 85, 153.
- (12) Chatterjee, D.; Lowell, K.; Rivoire, B.; McNeil, M. R.; Brennan, P. J. *J. Biol. Chem.* **1992**, 267, 6234.
- (13) Khoo, K. H.; Tang, J. B.; Chatterjee, D. *J. Biol. Chem.* **2001**, 276, 3863.
- (14) Liu, X.; Stocker, B. L.; Seeberger, P. H. *J. Am. Chem. Soc.* **2006**, 128, 3638.
- (15) Boonyarattanakalin, S.; Liu, X.; Michieletti, M.; Lepenies, B.; Seeberger, P. H. *J. Am. Chem. Soc.* **2008**, 130, 16791.
- (16) Jayaprakash, K. N.; Lu, J.; Fraser-Reid, B. *Angew. Chem., Int. Ed.* **2005**, 44, 5894.
- (17) Fraser-Reid, B.; Chaudhuri, S. R.; Jayaprakash, K. N.; Lu, J.; Ramarnurty, C. V. S. *J. Org. Chem.* **2008**, 73, 9732.
- (18) Fraser-Reid, B.; Lu, J.; Jayaprakash, K. N.; Lopez, J. C. *Tetrahedron: Asymmetry* **2006**, 17, 2449.
- (19) Ainge, G. D.; Compton, B. J.; Hayman, C. M.; Martin, W. J.; Toms, S. M.; Larsen, D. S.; Harper, J. L.; Painter, G. F. *J. Org. Chem.* **2011**, 76, 4941.
- (20) Ainge, G. D.; Parlane, N. A.; Denis, M.; Hayman, C. M.; Larsen, D. S.; Painter, G. F. *Bioorg. Med. Chem.* **2006**, 14, 7615.
- (21) Ainge, G. D.; Hudson, J.; Larsen, D. S.; Painter, G. F.; Gill, G. S.; Harper, J. L. *Bioorg. Med. Chem.* **2006**, 14, 5632.
- (22) Joe, M.; Bai, Y.; Nacario, R. C.; Lowary, T. L. *J. Am. Chem. Soc.* **2007**, 129, 9885.
- (23) Stadelmaier, A.; Biskup, M. B.; Schmidt, R. R. *Eur. J. Org. Chem.* **2004**, 3292.
- (24) Ainge, G. D.; Parlane, N. A.; Denis, M.; Dyer, B. S.; Harer, A.; Hayman, C. M.; Larsen, D. S.; Painter, G. F. *J. Org. Chem.* **2007**, 72, 5291.
- (25) Dyer, B. S.; Jones, J. D.; Ainge, G. D.; Denis, M.; Larsen, D. S.; Painter, G. F. *J. Org. Chem.* **2007**, 72, 3282.
- (26) Wang, H. R.; Ning, J. *J. Org. Chem.* **2003**, 68, 2521.
- (27) Hölemann, A.; Stocker, B. L.; Seeberger, P. H. *J. Org. Chem.* **2006**, 71, 8071.
- (28) Deng, L. M.; Liu, X.; Liang, X. Y.; Yang, J. S. *J. Org. Chem.* **2012**, 77, 3025.
- (29) D'Souza, F. W.; Ayers, J. D.; McCarren, P. R.; Lowary, T. L. *J. Am. Chem. Soc.* **2000**, 122, 1251.
- (30) Lu, J.; Fraser-Reid, B. *Chem. Commun.* **2005**, 862.
- (31) Watanabe, Y.; Yamamoto, T.; Ozaki, S. *J. Org. Chem.* **1996**, 61, 14.
- (32) Ishiwata, A.; Akao, H.; Ito, Y. *Org. Lett.* **2006**, 8, 5525.
- (33) Mereyala, H. B.; Hotha, S.; Gurjar, M. K. *Chem. Commun.* **1998**, 685.
- (34) D'Souza, F. W.; Lowary, T. L. *Org. Lett.* **2000**, 2, 1493.
- (35) Cao, B.; Williams, S. J. *Nat. Prod. Rep.* **2010**, 27, 919.
- (36) Patil, P. S.; Hung, S. C. *Org. Lett.* **2010**, 12, 2618.
- (37) Patil, P. S.; Hung, S. C. *Chem.—Eur. J.* **2009**, 15, 1091.
- (38) Jian, G.; Guo, Z. *J. Org. Chem.* **2013**, 78, 12717.
- (39) Kam, B. L.; Barascut, J. L.; Imbach, J. L. *Carbohydr. Res.* **1979**, 69, 135.
- (40) Huang, X.; Huang, L.; Wang, H.; Ye, X. S. *Angew. Chem., Int. Ed.* **2004**, 43, 5221.
- (41) Podlasek, C. A.; Wu, J.; Stripe, W. A.; Bondo, P. B.; Serianni, A. S. *J. Am. Chem. Soc.* **1995**, 117, 8635.
- (42) Mizutani, K.; Kasai, R.; Nakamura, M.; Tanaka, O.; Matsura, H. *Carbohydr. Res.* **1989**, 185, 27.
- (43) Yin, H.; D'Souza, F. W.; Lowary, T. L. *J. Org. Chem.* **2002**, 67, 892.